Global Second-Generation Antipsychotics Market Growth 2025-2031

The global Second-Generation Antipsychotics market size is predicted to grow from US$ 44760 million in 2025 to US$ 49650 million in 2031; it is expected to grow at a CAGR of 1.7% from 2025 to 2031.

Second-generation antipsychotics, also known as atypical antipsychotics or novel antipsychotics. Compared with the first generation drugs, the second generation antipsychotic drugs have significant differences in pharmacological mechanisms, clinical efficacy, and side effect profiles, making them the mainstream choice for the treatment of severe mental disorders such as schizophrenia and bipolar disorder. From the perspective of pharmacological mechanisms, second-generation antipsychotics can be divided into four categories: 5-hydroxytryptamine and dopamine receptor antagonists (such as risperidone, olanzapine, quetiapine, and ziprasidone), multi receptor acting drugs (such as clozapine), selective dopamine receptor antagonists (such as amisulpride), and dopamine receptor partial agonists (such as aripiprazole).

The global market for second-generation antipsychotics has shown a growth trend in recent years. Core products such as olanzapine, quetiapine, and risperidone have long dominated sales, while relatively new drugs such as aripiprazole and ziprasidone have also shown good growth momentum. The main driving factors of the market include the increasing burden of mental illness, changes in treatment concepts, increased policy support, and breakthroughs in research and development innovation. The market has significant regional differences. Currently, North America holds the largest market share, with multinational pharmaceutical giants such as Pfizer, Eli Lilly, Novartis, and Merck dominating the market. The European market follows closely behind, with a slightly slower growth rate than North America, but the competitive landscape is more fragmented with numerous participants. In the Asia Pacific region, the Japanese market is relatively small and growing slowly, dominated by several large local pharmaceutical companies. The Chinese and Indian markets are not large in scale, but their growth rates are significantly higher than the global average, making them key regions for global pharmaceutical companies to layout. In the future, market differentiation will intensify, and original drugs with expired patents will face fierce competition from generic drugs, resulting in a significant decrease in prices, while new mechanism drugs with significant clinical advantages can gain premium space. Early intervention for mental illness will receive more attention, and the demand for low-dose formulations and drugs with fewer side effects suitable for early intervention will increase. Digital health technologies such as electronic prescriptions, telemedicine, and medication compliance monitoring will be deeply integrated with antipsychotic drug treatment. Emerging economies such as China and India will become important engines of global growth. With the improvement of medical infrastructure and increased payment capacity, the demand for high-quality antipsychotic drugs will rapidly grow, providing strategic opportunities for global pharmaceutical companies.

LP Information, Inc. (LPI) ' newest research report, the “Second-Generation Antipsychotics Industry Forecast” looks at past sales and reviews total world Second-Generation Antipsychotics sales in 2024, providing a comprehensive analysis by region and market sector of projected Second-Generation Antipsychotics sales for 2025 through 2031. With Second-Generation Antipsychotics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Second-Generation Antipsychotics industry.

This Insight Report provides a comprehensive analysis of the global Second-Generation Antipsychotics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Second-Generation Antipsychotics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Second-Generation Antipsychotics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Second-Generation Antipsychotics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Second-Generation Antipsychotics.

This report presents a comprehensive overview, market shares, and growth opportunities of Second-Generation Antipsychotics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
5-Hydroxytryptamine And Dopamine Receptor Antagonists
Multi Receptor Acting Drugs
Selective Dopamine Receptor Antagonists
Dopamine Receptor Partial Agonists

Segmentation by Application:
Schizophrenia
Bipolar Disorder
Adjuvant Treatment For Depression
Other Mental Illnesses

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sumitomo Dainippon Pharma
Roche
Pfizer
Novartis
Otsuka Pharmaceutical
AbbVie
Johnson And Johnson
Ipsen
Merck
Eli Lilly
Luye Pharma Group
Nhwa Pharmaceutical
Livzon Pharmaceutical Group
Qilu Pharmaceutical
CSPC Pharmaceutical Group
Chengdu Kanghong Pharmaceutical
Hansoh Pharma
Hisun Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Yangtze River Pharmaceutical Group

Key Questions Addressed in this Report

What is the 10-year outlook for the global Second-Generation Antipsychotics market?

What factors are driving Second-Generation Antipsychotics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Second-Generation Antipsychotics market opportunities vary by end market size?

How does Second-Generation Antipsychotics break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.